Healio spoke with Chakra Chaulagain, MD, about phase 3 PERSEUS trial results presented at ASH 2023.
Findings from the randomized trial showed that among patients with newly diagnosed multiple myeloma, daratumumab (Darzalex, Janssen) combined with bortezomib (Velcade, Millenium/Takeda), lenalidomide (Revlimid, Bristol Myers Squibb) and dexamethasone was more effective than bortezomib, lenalidomide and dexamethasone alone.
“These data are really practice-changing,” Chaulagain, director of the myeloma and amyloidosis program at Cleveland Clinic Florida, told Healio. “We have been
